Percutaneous Right Ventricular Support via ProtekDuo Pulmonary Artery Cannulation
Year: 2025
Type: article
Study design: Observational Study
Abstract: ProtekDuo dual-lumen cannula implantation provides effective percutaneous right ventricular support in acute right heart failure. This retrospective study analyzed 60 patients who received ProtekDuo support for a mean of 14.9 ± 9.7 days. Hemodynamic improvements included reduced central venous pressure (17.8 ± 5.6-11.8 ± 5.0 mmHg, p < 0.001) and increased central venous oxygen saturation (60.6 ± 15.2-74.6% ± 7.8%, p < 0.001). End-organ function improved, with lower creatinine (2.9 ± 5.0-1.6 ± 0.8 mg/dl, p = 0.046) and lactate levels (26.0 ± 23.3-14.1 ± 10.4 mg/dl, p < 0.001). Bilirubin levels increased post-implantation (2.9 ± 3.2 to 5.7 ± 6.0 mg/dl, p < 0.001) but returned to baseline within 13.5 ± 19 days in weaned patients. Independent mortality risk factors were female sex (hazard ratio [HR] = 6.47, p < 0.001), older age (HR = 1.035, p = 0.036), and higher body mass index (BMI) (HR = 1.124, p = 0.003). These findings highlight the benefits of percutaneous ProtekDuo implantation in acute right heart failure, although patient selection remains critical. Further studies are needed to refine selection criteria and optimize outcomes.
Source: ASAIO Journal
Language: English
Subfield: Biomedical Engineering
Field: Engineering
Domain: Physical Sciences
Open Access status: hybrid
OpenAlex ID: W4416604167